RA Capital

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.

Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies. Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.

Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotech investigating novel therapeutics for CLDN1+ cancers. Alentis is the pioneering business in the use of anti-CLDN1 ADCs and antibodies to modify and reverse the progression of certain diseases.

Alpha-9 Oncology is a clinical-stage biotechnology company developing radiopharmaceuticals for solid and hematologic malignancies.

Our mission at ARS Pharmaceuticals is to provide at-risk patients and their families better protection from severe allergic reactions. We are developing a product that patients and their caregivers can use without anxiety or hesitation, confident in the effectiveness of both the product and the ability to administer it. We are developing ARS-1, a novel intranasal epinephrine spray with a unique absorption technology that could be easy to use, convenient, and more reliable for patients and loved ones at risk of severe allergic reactions to food, medications, and insect bites that could lead to life-threatening anaphylaxis.

Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic cancers or solid tumors. It was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technological barriers in the scaling and manufacturing of these cells. At Artiva, its mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva’s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates.

Developer of drug platform designed to address core problems in abnormal heart rhythms. The company's platform is used to identify antibodies that are responsible for abnormal heart rhythms in patients with arrhythmogenic right ventricular cardiomyopathy, cardiac sarcoid, and post-covid arrhythmias, enabling the patients to live longer and healthier lives.

Ascendis Pharma develops and markets innovative drugs for rare and orphan diseases like Transthyretin Amyloidosis and Congenital Adrenal Hyperplasia. Focus on unmet medical needs through global partnerships and R&D for life-changing treatments.

Asher bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases. Asher bio is backed by third rock ventures and is located in south san francisco.

Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar develops ATACs (ASGPR Targeting Chimeras), a new class of protein degrader therapeutics that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. Avilar has built a proprietary ATAC platform that includes novel, high-affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC-mediated endocytosis and degradation. The ATAC platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. Avilar is leveraging the ATAC platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. Avilar was founded and financed by RA Capital Management and is based in Waltham, MA.

Be bio is developing a proprietary class of engineered b cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.